ALPMF (Astellas Pharma) Tax Provision: $-565 Mil (TTM As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
72 GF Score
Price $14.60
GF Value $14.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Tax Provision?

Astellas Pharma ALPMF 72 Tax Provision is $-565 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 72/100 and a GF Value™ of $14.18 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's tax provision for the three months ended in Mar. 2026 was $-28 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $-565 Mil.

Astellas Pharma Tax Provision Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Tax Provision Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -276.61 -251.73 -52.89 130.89 -535.74

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.22 -152.23 -168.92 -215.72 -27.78
ALPMF
72GF Score
Astellas Pharma Inc ALPMF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-565 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-565 Mil mean?
Astellas Pharma (ALPMF) has a Tax Provision of $-565 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Tax Provision too high?
Astellas Pharma's current Tax Provision is $-565 Mil. Overall, Astellas Pharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Tax Provision compare to LLY and JNJ?
Astellas Pharma's Tax Provision of $-565 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Tax Provision is $-565 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $14.60 — trading 3% above its estimated fair value. The current Tax Provision is $-565 Mil. Astellas Pharma's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Tax Provision is $-565 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $14.60 is trading 3% above its estimated GF Value™ of $14.18. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Tax Provision: $-565 Mil
  • GF Value™: $14.18 vs. price of $14.60 (3% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
72GF Score

Get the complete analysis for ALPMF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.60
Price
$14.18
GF Value